Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma

References

• Villano JL, Koshy M, Shaikh H, et al. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011;105(9):1414–1418.  
   PubMed Web of Science ®Google Scholar
• Camilleri-Broët S, Crinière E, Broët P, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood. 2006;107(1):190–196.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ. How I treat primary CNS lymphoma. Blood. 2011;118(3):510–522.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Gupta NK, Mannis GN, et al. How I treat CNS lymphomas. Blood. 2013;122(14):2318–2330.   
   PubMed Web of Science ®Google Scholar
• Hoang-Xuan K, Bessell E, Bromberg J, et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol. 2015;16(7):e322-332–e332.
   Web of Science ®Google Scholar
• Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol.  2017;35(21):2410–2418.
   PubMed Web of Science ®Google Scholar
• Fox CP, Phillips EH, Smith J, et al. Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma. Br J Haematol. 2019;184(3):348–363.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in pts with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374(9700):1512–1520.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the international extranodal lymphoma study group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3(5):e217-227–e227.
   Web of Science ®Google Scholar
• Ferreri AJM, Cwynarski K, Pulczynski E, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the international extranodal lymphoma study group-32 phase 2 trial. Lancet Haematol. 2017;4(11):e510–e523.
   PubMed Web of Science ®Google Scholar
• Illerhaus G, Kasenda B, Ihorst G, et al. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematol. 2016;3(8):e388-397–e397.
   Web of Science ®Google Scholar
• Abrey LE, Moskowitz CH, Mason WP, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003;21(22):4151–4156.
   PubMed Web of Science ®Google Scholar
• DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation therapy oncology group study 93-10. J Clin Oncol. 2002;20(24):4643–4648.
   PubMed Web of Science ®Google Scholar
• Omuro A, Correa DD, DeAngelis LM, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125(9):1403–1410.
   PubMed Web of Science ®Google Scholar
• Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31(31):3971–3979.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)). J Clin Oncol. 2013;31(25):3061–3068.
   PubMed Web of Science ®Google Scholar
• Omuro A, Chinot O, Taillandier L, et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol. 2015;2(6):e251-259–e259.
   Web of Science ®Google Scholar
• Houillier C, Taillandier L, Dureau S, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol. 2019;37(10):823–833.
   PubMed Web of Science ®Google Scholar
• Fritsch K, Kasenda B, Hader C, et al. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol. 2011;22(9):2080–2085.  
   PubMed Web of Science ®Google Scholar
• Fritsch K, Kasenda B, Schorb E, et al. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia. 2017;31(4):846–852.
   PubMed Web of Science ®Google Scholar
• Hoang-Xuan K, Taillandier L, Chinot O, et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European organization for research and treatment of cancer brain tumor group. J Clin Oncol. 2003;21(14):2726–2731.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the international extranodal lymphoma study group experience. J Clin Oncol. 2003;21(2):266–272.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Ben-Porat L, Panageas KS, et al. Primary Central nervous system lymphoma: the memorial Sloan-Kettering cancer center prognostic model. J Clin Oncol. 2006;24(36):5711–5715.
   PubMed Web of Science ®Google Scholar
• Löw S, Han CH, Batchelor TT. Primary central nervous system lymphoma. Ther Adv Neurol Disord. 2018;11:1756286418793562.
   Web of Science ®Google Scholar
• Grisariu S, Shapira MY, Or R, et al. Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) conditioning regimen for autologous stem cell transplantation in lymphoma. Clin Lymphoma Myeloma Leuk. 2018;18(4):272–279.  
   PubMed Web of Science ®Google Scholar
• Pels H, Juergens A, Schirgens I, et al. Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma. Neuro Oncol. 2010;12(7):720–724.
   PubMed Web of Science ®Google Scholar
• Schorb E, Fox CP, Kasenda B, et al. Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system – an international study of feasibility and efficacy in routine clinical practice. Br J Haematol. 2020;189(5):879–887.
   PubMed Web of Science ®Google Scholar